antipyrine has been researched along with Cardiac Failure in 8 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Edaravone suppressed plasma MCP-1, improved left ventricular ejection fraction, and reduced rehospitalization due to heart failure." | 9.14 | Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction. ( Chitose, T; Fukuda, M; Kaikita, K; Nagata, T; Nagayoshi, Y; Nakamura, Y; Nako, H; Ogawa, H; Ogura, Y; Ohba, K; Shimomura, H; Soejima, H; Sugiyama, S; Tsujita, K; Yamada, Y; Yamaguchi, M; Yamashita, T, 2009) |
| "Edaravone suppressed plasma MCP-1, improved left ventricular ejection fraction, and reduced rehospitalization due to heart failure." | 5.14 | Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction. ( Chitose, T; Fukuda, M; Kaikita, K; Nagata, T; Nagayoshi, Y; Nakamura, Y; Nako, H; Ogawa, H; Ogura, Y; Ohba, K; Shimomura, H; Soejima, H; Sugiyama, S; Tsujita, K; Yamada, Y; Yamaguchi, M; Yamashita, T, 2009) |
| "During the development of heart failure, edaravone ameliorated the defective interdomain interaction of the RyR2." | 3.73 | Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. ( Doi, M; Ikeda, Y; Ikemoto, N; Kobayashi, S; Matsuzaki, M; Mochizuki, M; Noma, T; Oda, T; Ohkusa, T; Okuda, S; Tateishi, H; Tokuhisa, T; Yamamoto, T; Yano, M, 2005) |
| "Antipyrine was used to assess the status of drug metabolism in ten female patients with congestive cardiac failure." | 3.66 | Alteration of hepatic drug metabolism in female patients with congestive cardiac failure. ( Anand, IS; Madappa, C; Nair, CR; Rissam, HS; Wahi, PL, 1983) |
| " Hepatic pharmacokinetic modelling was performed with a two-phase physiologically-based organ pharmacokinetic model with the vascular space and dispersion evaluated with the MID technique." | 1.38 | Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012) |
| "In six patients without cardiac failure the plasma concentrations of lignocaine rose progressively during the infusion and the mean lignocaine half life was 4." | 1.26 | Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure. ( Adjepon-Yamoah, KK; Prescott, LF; Talbot, RG, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, Y | 1 |
| Yamada, Y | 1 |
| Shimomura, H | 1 |
| Nagayoshi, Y | 1 |
| Tsujita, K | 1 |
| Yamashita, T | 1 |
| Fukuda, M | 1 |
| Ohba, K | 1 |
| Nako, H | 1 |
| Ogura, Y | 1 |
| Chitose, T | 1 |
| Yamaguchi, M | 1 |
| Nagata, T | 1 |
| Soejima, H | 1 |
| Kaikita, K | 1 |
| Sugiyama, S | 1 |
| Ogawa, H | 1 |
| Li, P | 1 |
| Robertson, TA | 1 |
| Zhang, Q | 1 |
| Fletcher, LM | 1 |
| Crawford, DH | 1 |
| Weiss, M | 1 |
| Roberts, MS | 1 |
| Yano, M | 1 |
| Okuda, S | 1 |
| Oda, T | 1 |
| Tokuhisa, T | 1 |
| Tateishi, H | 1 |
| Mochizuki, M | 1 |
| Noma, T | 1 |
| Doi, M | 1 |
| Kobayashi, S | 1 |
| Yamamoto, T | 1 |
| Ikeda, Y | 1 |
| Ohkusa, T | 1 |
| Ikemoto, N | 1 |
| Matsuzaki, M | 1 |
| Rissam, HS | 1 |
| Nair, CR | 1 |
| Anand, IS | 1 |
| Madappa, C | 1 |
| Wahi, PL | 1 |
| Masson, JP | 1 |
| Bass, O | 1 |
| Baur, HR | 1 |
| Ohnhaus, EE | 1 |
| Adamska-Dyniewska, H | 1 |
| Prescott, LF | 1 |
| Adjepon-Yamoah, KK | 1 |
| Talbot, RG | 1 |
| Sycheva, IM | 1 |
| Vinogradov, AV | 1 |
| Kuz'mina, AE | 1 |
| Kiseleva, ZM | 1 |
1 trial available for antipyrine and Cardiac Failure
| Article | Year |
|---|---|
Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Antipyrine; Biomarkers; Chemokine CCL2; Edaravone; Female; Fre | 2009 |
7 other studies available for antipyrine and Cardiac Failure
| Article | Year |
|---|---|
Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Topics: Adrenergic Antagonists; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2012 |
Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure.
Topics: Animals; Antioxidants; Antipyrine; Calcium; Cardiac Pacing, Artificial; Dogs; Edaravone; Heart Failu | 2005 |
Alteration of hepatic drug metabolism in female patients with congestive cardiac failure.
Topics: Adolescent; Adult; Alanine Transaminase; Alkaline Phosphatase; Antipyrine; Bilirubin; Blood Proteins | 1983 |
[The pharmacokinetics of digoxin during chronic spironolacton treatment (author's transl)].
Topics: Adult; Aged; Antipyrine; Digoxin; Feces; Female; Half-Life; Heart Failure; Humans; Kinetics; Male; M | 1978 |
[Liver capacity in the biotransformation of drugs in patients with chronic circulatory failure (kinetics of antipyrine and indocyanine green)].
Topics: Antipyrine; Biotransformation; Heart Failure; Humans; Indocyanine Green; Kinetics; Liver | 1978 |
Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.
Topics: Adult; Aged; Antipyrine; Half-Life; Heart Failure; Humans; Lidocaine; Male; Middle Aged; Myocardial | 1976 |
[Distribution of fluid between the cells and the extracellular media and mineralocorticoid function of the adrenal glands in cardiac insufficiency].
Topics: Adrenal Glands; Adult; Aldosterone; Antipyrine; Body Fluids; Chromatography, Paper; Coronary Disease | 1969 |